Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 242

1.

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD.

BMC Cancer. 2007 Jul 24;7:134.

PMID:
17650314
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

PMID:
17146782
[PubMed - indexed for MEDLINE]
Free Article
3.

Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.

BMC Cancer. 2010 May 21;10:223. doi: 10.1186/1471-2407-10-223.

PMID:
20492711
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S.

Anticancer Res. 2007 Jan-Feb;27(1B):547-55.

PMID:
17348440
[PubMed - indexed for MEDLINE]
Free Article
5.

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.

Breast Cancer Res. 2007;9(1):R16.

PMID:
17263897
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.

Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T.

J Surg Oncol. 2008 Jan 1;97(1):30-4.

PMID:
17929254
[PubMed - indexed for MEDLINE]
7.

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.

PMID:
17234468
[PubMed - indexed for MEDLINE]
8.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

PMID:
18316557
[PubMed - indexed for MEDLINE]
Free Article
9.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

PMID:
19414985
[PubMed - indexed for MEDLINE]
Free Article
10.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
[PubMed - indexed for MEDLINE]
11.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
[PubMed - indexed for MEDLINE]
12.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
[PubMed - indexed for MEDLINE]
13.

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Bryan BB, Schnitt SJ, Collins LC.

Mod Pathol. 2006 May;19(5):617-21.

PMID:
16528377
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
[PubMed - indexed for MEDLINE]
15.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
[PubMed - indexed for MEDLINE]
16.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
[PubMed - indexed for MEDLINE]
17.

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6. doi: 10.1016/j.humpath.2007.07.014.

PMID:
18261623
[PubMed - indexed for MEDLINE]
18.

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Dabbs DJ, Chivukula M, Carter G, Bhargava R.

Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

PMID:
16941011
[PubMed - indexed for MEDLINE]
Free Article
19.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
[PubMed - indexed for MEDLINE]
20.

Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.

Marotti JD, Collins LC, Hu R, Tamimi RM.

Mod Pathol. 2010 Feb;23(2):197-204. doi: 10.1038/modpathol.2009.158. Epub 2009 Nov 6.

PMID:
19898422
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk